Phase II Study , Association of Cisplatine Topotecan and Cetuximab in Patients Whith Late or in Progress Epithelial Cancer of the Cervix (ERBUS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00518193|
Recruitment Status : Terminated (high rate of medullar aplasia with infectious troubles.)
First Posted : August 20, 2007
Last Update Posted : June 30, 2011
The efficacy of chimiotherapy in cervix epithelial cancer is low even with the association cisplatine - topotecan .
News thérapeutics are needed in the goal of increase the survival and quality of life in patients with cervix cancer.
Cetuximab has shown the potentialisation on the efficacy of cisplatine and irinotecan.
Cisplatine and topotecan have shown an efficacy in cervix cancer. Cetuximab is well tolerate. Many clinical trials shown the faisability of the association of cetuximab and cisplatine in cancer.
Many clinical trials have shown the faisability of association of cetuximab and irinotecan in colorectals metastatiques cancers .
|Condition or disease||Intervention/treatment||Phase|
|Cervix Cancer||Drug: ERBITUX||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||44 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||April 2007|
|Actual Primary Completion Date :||July 2007|
|Actual Study Completion Date :||September 2008|
- responses rate regarding the RECIST criteria. [ Time Frame: up to progression ]
- Quality of life, free interval, safety. [ Time Frame: up to progression ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00518193
|CRLC Val d'Aurelle|
|Montpellier, France, 34298|
|Hôpital HOTEL DIEU|
|Paris, France, 75004|
|Oncologie, Hôtel-Dieu, 1 place du parvis Notre-Dame|
|Paris, France, 75004|
|Centre Claudius Régaud|
|Toulouse, France, 31052|
|Principal Investigator:||Pr KURTZ Jean Emmanuel||STRASBOURG|